Free Trial
NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

X4 Pharmaceuticals logo
$1.47 -0.10 (-6.31%)
As of 02:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About X4 Pharmaceuticals Stock (NASDAQ:XFOR)

Key Stats

Today's Range
$1.45
$1.56
50-Day Range
$1.57
$4.30
52-Week Range
$1.46
$26.96
Volume
345,832 shs
Average Volume
141,528 shs
Market Capitalization
$8.57 million
P/E Ratio
0.69
Dividend Yield
N/A
Price Target
$72.33
Consensus Rating
Buy

Company Overview

X4 Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

XFOR MarketRank™: 

X4 Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    X4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    X4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about X4 Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.68) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of X4 Pharmaceuticals is 0.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.84.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of X4 Pharmaceuticals is 0.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

  • Price to Book Value per Share Ratio

    X4 Pharmaceuticals has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about X4 Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.63% of the float of X4 Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in X4 Pharmaceuticals has recently increased by 22.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    X4 Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    X4 Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.63% of the float of X4 Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in X4 Pharmaceuticals has recently increased by 22.15%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    X4 Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    Only 4 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, X4 Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,559.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 2.37% of the stock of X4 Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about X4 Pharmaceuticals' insider trading history.
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Stock News Headlines

X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 0.3% - Should You Sell?
X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
President Trump’s Project MAFA
President Trump’s Boldest Initiative Yet First came “Make America Great Again” (MAGA)… Then came “Make America Healthy Again” (MAHA)… Now comes President Trump’s boldest initiative yet. After a gathering in D.C. with some of the most powerful people in the world, Jeff Brown is now revealing the full details on “Project MAFA.” It’s a revolutionary plan to return America to an era of sound money, eliminate our looming debt disaster, kick off a Golden Century, and more – by July 25. Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. Jeff Brown is sharing the details Wednesday, July 16, at 8 p.m. ET – including the name of a stock set to profit.
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
See More Headlines

XFOR Stock Analysis - Frequently Asked Questions

X4 Pharmaceuticals' stock was trading at $22.0080 at the start of the year. Since then, XFOR shares have decreased by 93.3% and is now trading at $1.48.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced its earnings results on Thursday, May, 1st. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($4.13) by $4.17. The firm earned $28.81 million during the quarter, compared to analysts' expectations of $7.03 million. X4 Pharmaceuticals had a net margin of 46.54% and a negative trailing twelve-month return on equity of 181.56%.
Read the conference call transcript
.

X4 Pharmaceuticals's stock reverse split before market open on Monday, April 28th 2025.The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Intel (INTC).

Company Calendar

Last Earnings
5/01/2025
Today
7/11/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XFOR
CIK
1501697
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$120.00
Low Price Target
$7.00
Potential Upside/Downside
+4,507.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.14
Trailing P/E Ratio
0.73
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.45 million
Net Margins
46.54%
Pretax Margin
47.58%
Return on Equity
-181.56%
Return on Assets
-54.36%

Debt

Debt-to-Equity Ratio
3.30
Current Ratio
3.70
Quick Ratio
3.58

Sales & Book Value

Annual Sales
$2.56 million
Price / Sales
3.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.90 per share
Price / Book
0.40

Miscellaneous

Outstanding Shares
5,790,000
Free Float
5,652,000
Market Cap
$9.09 million
Optionable
Optionable
Beta
0.54
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:XFOR) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners